10-K
Annual Report
ACTINIUM PHARMACEUTICALS, INC.
ATNM
NYSE
CIK: 1388320
File #: 001-36374
Balance Sheet
28 line items · 2 periods
XBRL
| Item | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 72,904,000 | 76,677,000 |
Prepaid expenses and other current assets | 1,602,000 | 1,586,000 |
Total Current Assets | 74,506,000 | 78,263,000 |
Property and equipment, net of accumulated depreciation of $891 and $694 | 364,000 | 550,000 |
Restricted cash – long term | 324,000 | 313,000 |
Operating lease right-of-use assets | 1,685,000 | 2,289,000 |
Finance leases right-of-use assets | 20,000 | 30,000 |
Total Assets | 76,899,000 | 81,445,000 |
Liabilities and Stockholders’ Equity | ||
Current Liabilities: | ||
Accounts payable and accrued expenses | 7,568,000 | 7,953,000 |
Operating leases current liability | 569,000 | 530,000 |
Finance leases current liability | 11,000 | 11,000 |
Total Current Liabilities | 8,148,000 | 8,494,000 |
Long-term license revenue deferred | 35,000,000 | 35,000,000 |
Long-term operating lease obligations | 984,000 | 1,553,000 |
Long-term finance lease obligations | 9,000 | 19,000 |
Total Liabilities | 44,141,000 | 45,066,000 |
Stockholders’ Equity: | ||
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 27,634,213 shares issued and outstanding at December 31, 2024 and 2023, respectively | 31,000 | 28,000 |
Additional paid-in capital | 408,553,000 | 373,934,000 |
Accumulated deficit | (375,826,000) | (337,583,000) |
Total Stockholders’ Equity | 32,758,000 | 36,379,000 |
Common Stock | 31,000 | 28,000 |
Additional Paid-In Capital | 408,553,000 | 373,934,000 |
Accumulated Deficit | (375,826,000) | (337,583,000) |
Total Liabilities and Stockholders’ Equity | 76,899,000 | 81,445,000 |